JY
COGT icon

Jeff Yass’s Cogent Biosciences COGT Stock Holding History

Jeff Yass’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.47M Sell
193,100
-86,800
-31% -$3.04M ﹤0.01% 3872
2026
Q1 		$10.8M Sell
279,900
-36,900
-12% -$1.36M ﹤0.01% 3009
2025
Q4 		$11.3M Buy
316,800
+45,800
+17% +$1.29M ﹤0.01% 2901
2025
Q3 		$3.89M Buy
271,000
+168,500
+164% +$2M ﹤0.01% 4518
2025
Q2 		$736K Buy
+102,500
New +$568K ﹤0.01% 8225
2025
Q1 		– Sell
-100,900
Closed -$787K – 12587
2024
Q4 		$787K Buy
100,900
+86,800
+616% +$865K ﹤0.01% 7552
2024
Q3 		$152K Sell
14,100
-11,300
-44% -$110K ﹤0.01% 10725
2024
Q2 		$214K Buy
25,400
+1,200
+5% +$9.1K ﹤0.01% 10209
2024
Q1 		$163K Buy
+24,200
New +$150K ﹤0.01% 10828
2023
Q4 		– Sell
-15,000
Closed -$146K – 12454
2023
Q3 		$146K Buy
+15,000
New +$178K ﹤0.01% 10565
2022
Q3 		– Sell
-22,100
Closed -$199K – 13270
2022
Q2 		$199K Buy
+22,100
New +$151K ﹤0.01% 10640

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Jeff Yass's COGT Position: Q2 2026 in Review

Jeff Yass increased its Cogent Biosciences (COGT) stake by 296% in Q2 2026, buying an estimated $7.3M and bringing the position to 279,066 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3281.

Jeff Yass first reported a position in COGT in Q3 2018 and has held it in 20 quarters since. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Jeff Yass held 279,066 shares of Cogent Biosciences worth $10.8M as of Q2 2026.
  • Jeff Yass bought 208,588 Cogent Biosciences shares in Q2 2026, an estimated $7.3M.
  • Cogent Biosciences made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #3281 holding.
  • Jeff Yass first reported a position in Cogent Biosciences in Q3 2018 and has held it in 20 quarters since.
  • 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.